Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Sofia Elverdin Selected as Co-Recipient of the Best Dissertation Prize From the American Political Science Association’s Women, Gender and Politics Section